11th World ADC Europe 2021
08 March 2021 - 11 March 2021Summary
Europe's Definitive Antibody-Drug Conjugate EventOverview
Now in its 11th year, World ADC Europe prides itself in being the industry-leading conference to help forward thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates.
Since the last World ADC London in March of 2020, we have seen huge progress within the ADC field with the approval of Trodelvy from Immunomedics, Blenrep from GSK - and now with ADC Therapeutics submitting their BLA in September of 2020, could this be the next approved ADC?
Join fellow experts virtually across 140+ active organisations as they unite at this industry focussed digital conference to learn the latest ADC intelligence, foster new connections and develop business relationships with partners.
This year, you can be part of Europe's longest standing and most comprehensive ADC conference from the comfort and safety of your workplace and continue to power the development of your ADC pipeline in 2021.
For more information, visit: www.worldadc-europe.com
Time: 09:00 to 17:00
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
Drug Developer Pricing - Conference (2 Day Pass): GBP 1499.00,
Service Provider Pricing - Conference (2 Day Pass): GBP 1799.00,
Academic Pricing - Conference Only - Conference (2 Day Pass): GBP 1199.00
Speakers: Adam Taylor, Scientist, Defence Science and Technology Laboratory - DSTL, Agnieska Czechowicz, Assistant Professor of Pediatrics, Stanford University School of Medicine, Alain Beck, Senior Director, Biologics CMC and developability, Pierre Fabre, Anand Subramony, Vice President, Antibody Discovery and Protein Engineering, R and D, AstraZeneca, Andre Dumetz, Senior Scientific Investigator, GlaxoSmithKline, Arturo Molina, Chief Medical Officer, Sutro Biopharma, Bob Bayer, Director of CMC Drug Development, Tanabe Research Laboratories, Bob Liu, Senior Scientist, CytomX, Brian Lannuttim, Senior Vice President - Research and Development, Velosbio, Brian Mendelsohn Director, Process Development and Tech Transfer, Ajinomoto Bio-Pharma Services, Christopher Scott, Professor - Pharmaceutical Biosciences Queen's University, Belfast, David Newman, Independent Consultant, Donald Mager, Professor and Vice Chair of Pharmaceutical Sciences, University at Buffalo, Dorota Roberts, Associate Director Technical Product Steward - Biologics, Seattle Genetics, Ed Ha, Founding Principal Scientist, AngieX, Elizabeth Love, Senior Scientist - Drug conjugates, Biologics and Analysis, LideArc, Francesca Zammarchi, Head of Pharmacology, ADC Therapeutics, Futa Mimoto, Research Manager, Chugai Pharmaceuticals, Gareth Thomas, Professor - Experimental Pathology, University of Southampton, Gavin Bennett, Director and Project Leader, Bicycle Therapeutics, Gilles Gallant, Senior Vice President, Global Head of Oncology Development, Oncology R and D Daiichi Sankyo, Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals, Gordon Rigg, Principal Consultant, Apex Biologics Consulting, Ian Schwartz, Global Biconjugate and Antibody-Drug Conjugates Consultant. Sartorius, Horst Bierau, Senior Scientific Advisor – Head CMC Science and Intelligence, Merck, Jia He, Analyst, Beacon Target Therapies, John Harlan, Senior Principal Research Scientist, AbbVie, John Lambert, Independent Consultant, Attager Consulting, Jon Van Dyck, Scientist, Seattle Genetics, Jostein Dahl, Chief Scientific Officer, Nordic Nanovector, Krista Kinneer, Senior Scientist, AstraZeneca, Lolke de haan, Head of Toxicology, ADC Therapeutics, Maria Laura Greco, Marie Curie Research Fellow, AstraZeneca, and more.More Information »